Use of Oral Corticosteroids and Risk of Hip Fracture in the Elderly in a Case-Control Study

Lai, Shih‐Wei; Lin, Cheng‐Li; Liao, Kuan‐Fu

doi:10.3389/fphar.2017.00625

Cited by 18 publications

(8 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, only subjects whose cumulative duration of zolpidem use was ≥12 months were included. The definition of medication exposure was adapted from previous studies ( Cheng et al, 2017 ; Lai et al, 2017 ; Liao et al, 2017c , d ). Subjects who did not have a prescription for medications studied were classified as never use.…”

Section: Methodsmentioning

confidence: 99%

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

Background/Objectives: Previous studies showed that zolpidem use could be associated with increased cancer risk, but the role of zolpidem on hepatocellular carcinoma (HCC) risk remains undetermined. The study purpose was to examine the association between HCC risk and zolpidem use in Taiwan.Methods: Using the database from the Taiwan National Health Insurance Program, we designed a case-control study which consisted of 77986 subjects aged 20 years or older with newly diagnosed HCC as the case group, and 77986 subjects without HCC as the control group, from 2000 to 2011. Ever use of zolpidem was defined as a subject who had at least a prescription for zolpidem before the index date. Never use was defined as a subject who did not have a prescription for zolpidem before the index date. The association between HCC risk and zolpidem use was determined by the odds ratio (OR) and 95% confidence interval (CI) in a multivariable logistic regression model.Results: After adjustment for confounding factors, the adjusted OR of HCC was 1.05 (95% CI 0.97, 1.13) for subjects with ever use of zolpidem, compared with never use of zolpidem. The adjusted OR of HCC was 1.01 for subjects with increasing cumulative duration of zolpidem use for every 1 year (95% CI 0.99, 1.03), compared with never use of zolpidem.Conclusion: There is no significant association between HCC risk and zolpidem use. There is no duration-dependent effect of zolpidem use on HCC risk.

show abstract

Section: Methodsmentioning

confidence: 99%

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Comorbidities before the index date were selected as follows: alcohol-related disease, cardiovascular disease (including coronary artery disease, heart failure, cerebrovascular disease, and peripheral atherosclerosis), chronic kidney disease, chronic obstructive pulmonary disease, hyperlipidemia, hypertension, hip fracture, thalassemia, and oral corticosteroid use. All comorbidities were diagnosed based on ICD-9 codes, which have been well assessed in previous studies (9)(10)(11).…”

Section: Comorbidities Studiedmentioning

confidence: 99%

Real-World Database Examining the Association Between Avascular Necrosis of the Femoral Head and Diabetes in Taiwan

2018

Self Cite

View full text Add to dashboard Cite

OBJECTIVENo study has been conducted to evaluate the association between avascular necrosis of the femoral head and diabetes. This study's aim was to assess this issue in Taiwan. RESEARCH DESIGN AND METHODSA population-based cohort study was performed to analyze the database of Taiwan's National Health Insurance Program. There were 27,869 subjects aged 20-84 years with newly diagnosed diabetes from 2000 to 2012 as the group with diabetes. The group without diabetes included 111,476 sex-and age-matched subjects without diabetes. The incidence of avascular necrosis of the femoral head at the end of 2013 was measured. A multivariable Cox proportional hazards regression model was used to measure the hazard ratio (HR) and 95% CI for avascular necrosis of the femoral head associated with diabetes. RESULTSThe overall incidence of avascular necrosis of the femoral head was 1.37-fold higher in the group with diabetes than in the group without diabetes (6.53 vs. 4.76 per 1,000 person-years [95% CI 1.31-1.43]). After adjusting for confounders, the HR of avascular necrosis of the femoral head was 1.16 (95% CI 1.11-1.21) for the subjects with diabetes compared with the subjects without diabetes. CONCLUSIONSPatients with diabetes have a 1.16-fold increased risk for developing avascular necrosis of the femoral head.Avascular necrosis of the femoral head is an important clinical issue. It is a debilitating complication resulting from the vascular compromise of the femoral head, which leads to the death of bone cells, femoral head collapse, irreversible destruction of the hip joint, and eventually total hip arthroplasty (1,2). Microvascular and macrovascular complications of diabetes have been well established (3,4), but an association between avascular necrosis of the femoral head and diabetes has not been previously described. To address this issue, a population-based retrospective cohort study was performed to analyze the database of Taiwan's National Health Insurance Program. RESEARCH DESIGN AND METHODS Study Design and Data Source

show abstract

“…e increasing population of PLA, as well as the PLA survivors, underscores the importance of identifying the long-term sequelae of PLA. e use of oral corticosteroids is significantly associated with an increased risk of developing PLA with a dose-dependent effect [5,6].…”

Section: Introductionmentioning

confidence: 99%

The Epidemiology of Hip Fracture among Subjects with Pyogenic Liver Abscess (PLA): A Nationwide Population-Based Study

Hsu

Lin

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Pyogenic liver abscess (PLA) is a potentially fatal disease that can stimulate prominent systemic inflammation. Osteoporotic hip fracture is a major complication of systemic inflammation. This study tried to determine the epidemiology of hip fractures among PLA patients. All subjects admitted due to PLA during 1999∼2010 were assessed, excluding the subjects with a history of high energy trauma, malignancy, and previous hip fracture. We matched the control subjects to PLA patients according to age, gender, and the coding of osteoporosis by 1 : 4 ratio. The PLA patients had a 1.17-fold risk of hip fracture than the controls (aHR = 1.17, 95% CI = 1.07–1.29) after adjusting for gender, age, and comorbidities. Considering death as the competing event of suicide, the PLA patients had 1.10-fold suicide risk (aHR = 1.10, 95% CI: 1.00–1.21) than the control subjects under the competing risks regression model. The cumulative incidence of hip fracture was higher in the PLA cohort (log-rank test, p<0.001). When compared to the controls, the fracture risk was 18.4-fold (aHR = 18.4, 95% CI = 13.0–26.1) for the PLA patients admitted 2-3 times per year and 46.0-fold (aHR = 46.0, 95% CI = 31.2–67.8) for the PLA patients admitted ≧4 times per year. The impact of PLA is more prominent among the subjects aged <45 years (aHR = 2.81, 95% CI = 1.42–5.56). Preventive measures for hip fracture might be warranted for PLA patients.

show abstract

Use of Oral Corticosteroids and Risk of Hip Fracture in the Elderly in a Case-Control Study

Cited by 18 publications

References 48 publications

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Zolpidem Administration and Risk of Hepatocellular Carcinoma: A Case-Control Study in Taiwan

Real-World Database Examining the Association Between Avascular Necrosis of the Femoral Head and Diabetes in Taiwan

The Epidemiology of Hip Fracture among Subjects with Pyogenic Liver Abscess (PLA): A Nationwide Population-Based Study

Contact Info

Product

Resources

About